crypto worth snippets

The Bank of Italy said that the economy may only grow by 0.5% this year, and the Bank of Italy said in a statement on Friday that the gross domestic product (GDP) will increase by 0.5% in 2024. If seasonal and calendar effects are not taken into account, this figure will increase to 0.7%, but it is lower than the government's estimate of 1% in the budget. In addition, GDP growth is expected to be 0.8% in 2025 and 1.1% in 2026. It is estimated that the unified average inflation rate in the EU will be 1.1% in 2024, which is the same as the estimated value in October, 1.5% in 2025 and 1.6% in 2025.Russian Ministry of Defence: Russian armed forces occupied seven settlements in one week.Market news: Hungary and Bulgaria find solutions for Russian natural gas transportation.

Kang Enbei: Amikacin Sulfate Injection is planned to win the bid for the tenth batch of national centralized drug purchase. On December 12th, Kang Enbei and its wholly-owned subsidiary Jinhua Kang Enbei participated in the bidding for the tenth batch of national centralized drug purchase organized by the National Joint Procurement Office for Centralized Drug Purchase and Use. After the bid opening and bid evaluation by the Joint Procurement Office, the company's product Amikacin Sulfate Injection plans to win the bid for this centralized procurement, and the supply provinces have been selected according to the market potential of each province. The successful results will be officially released after being publicized by the Joint Procurement Office. Amikacin sulfate injection is suitable for the treatment of serious infections caused by Pseudomonas aeruginosa, other Pseudomonas, Escherichia coli and other sensitive gram-negative bacilli and Staphylococcus (methicillin-sensitive strains). Compared with the original price, the price of the product to be selected this time has dropped to a certain extent.Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.Market News: Turkish anti-monopoly agency fined Google $75 million for advertising technology investigation.

Keheng shares: signed a cooperation framework agreement with Gree supply chain, and Keheng shares announced that the company and its wholly-owned subsidiaries Yingde Keheng, Zhuhai Keheng, Zhuhai Haoneng and Haoneng Technology signed a cooperation framework agreement with Gree supply chain. Gree supply chain granted Jiangmen Keheng, Yingde Keheng, Zhuhai Keheng, Zhuhai Haoneng and Haoneng Technology a total of 650 million yuan in raw material procurement business.Contemporary Amperex Technology Co., Limited traded 175,000 shares today with a turnover of 44,625,200 yuan, while Contemporary Amperex Technology Co., Limited traded 175,000 shares today with a turnover of 44,625,200 yuan, accounting for 0.58% of the total turnover of the day. The average transaction price was 255 yuan, which was 4.51% lower than the market closing price of 267.03 yuan, of which the highest transaction price was 267.03 yuan and the lowest transaction price was 218.97 yuan.The balance of A-share financing reached a new high in nine years. Since the fourth quarter, the net purchase amount of financing in 12 industries has exceeded 10 billion yuan. As of December 12, the balance of A-share financing was 1,882.656 billion yuan, a new high since August 2015. Since the fourth quarter, the market financing balance has grown rapidly. The latest financing balance was 1,882.656 billion yuan, an increase of 452.006 billion yuan or 31.59% compared with the financing balance of 1,430.650 billion yuan on September 30. During the period, the net purchase amount of financing in 12 industries exceeded 10 billion yuan. Electronics, computers, non-bank finance and machinery and equipment ranked in the top four, with the amounts of 77.849 billion yuan, 50.709 billion yuan, 49.201 billion yuan and 31.068 billion yuan in turn. In proportion, the latest financing balance of electronics, mechanical equipment and computers increased by more than 50% compared with that before the fourth quarter; The growth rate of media, communications and automobiles is also higher than 40%. In terms of individual stocks, Oriental Fortune received the most financing customers, with a net purchase amount of 15.892 billion yuan; SMIC ranked second with a net purchase of 5.515 billion yuan; Jianghuai Automobile ranked third with a net purchase of 4.122 billion yuan. Among the TOP20 stocks, there are many non-bank financial, automobile, computer and semiconductor stocks, accounting for 50% of the total. (data treasure)